News

Neurotrope has finished dosing and monitoring patients in a Phase 2 clinical trial to evaluate Bryostatin-1, the company’s lead drug candidate for treatment of moderate to severe Alzheimer’s disease. The randomized, double-blind, placebo-controlled, Phase 2 clinical trial (NCT02431468) is assessing the safety, tolerability and efficacy of bryostatin-1 in 148 people…

The Vanderbilt University Medical Center has passed a key hurdle in its quest to develop a treatment for Alzheimer’s disease with the announcement that the U.S. Food and Drug Administration (FDA) has approved a Phase 1 clinical trial of the therapy. The development marks one of the few times that a university…

Yet another Alzheimer’s disease clinical trial (NCT01741194) has ended in disappointment. Accera, noting that its Phase 3 trial of AC-1204 showed the drug offered no benefits over placebo, blamed its failure on an inadequate uptake of AC-1204 into the bloodstream. “The trial result is disappointing for us and the millions…

Factors known to increase risk for heart disease during middle age – diabetes, high blood pressure and smoking – also raise the risk of dementias such as Alzheimer’s disease later in life. So concludes a study presented at the American Stroke Association’s International Stroke Conference 2017, held Feb. 22-24, in Houston,…

Increased blood sugar levels may lead to Alzheimer’s disease by damaging a protein that is essential in fighting the disease’s early stages, a new study indicates. The report, “Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer’s Disease,” appeared in the journal Scientific Reports. Diabetes is a…

Sleeping for more than nine hours each night may predict the risk of developing dementia, and people who sleep a lot tend to have smaller brains. Those are among the findings in a new study, “Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia,” that appeared recently in the…

Spanish researchers have developed an artificial-intelligence system to help doctors diagnose Alzheimer’s disease. The system, based on brain-scan analysis, can also detect when a person suffers from the mild cognitive impairment that can signal that a person has Alzheimer’s. Doctors can use the tool to make earlier diagnoses. Alzheimer’s-related processes…

Rush University Medical Center in Chicago will investigate risk factors for Alzheimer’s disease among Latinos, a study it hopes will shed light on how Hispanics age. The decision to do the research comes at time when scientists are predicting a nine-fold increase in Alzheimer’s cases among those of Latin American descent…

A report supported by the World Health Organization lists 59 research priorities the authors believe would reduce the burden of dementia in the coming decade. A commentary in the same issue of The Lancet Neurology ripped the report’s positions, however, touching off a back-and-forth between the sides. The report, “Research priorities…

Merck is calling off its Phase 2 and 3 EPOCH trial of verubecestat as a treatment for mild-to-moderate Alzheimer’s disease because preliminary results indicate it is not effective. The decision was made after an external review board known as the Data Monitoring Committee (eDMC) reported there was “virtually no chance of finding…